常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
1.66/2.08
|
|
企業價值
1.92B
|
| 資產負債 |
|
每股賬面淨值
13.51
|
| 現金流量 |
|
現金流量率
0.10
|
| 損益表 |
|
收益
358.71M
|
|
每股收益
3.88
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/16 13:48 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. |

22.25 
